SCHEMBL981422

SCHEMBL981422

O=C(C(Br)=Cc1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 1/20 0.53
CES2 O00748 6/20 0.52
CES1 P23141 5/20 0.52
AKR1C3 P42330 1/20 0.50
MAPT P10636 5/20 0.46
KMT2A Q03164 4/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
FBP1 P09467 1/20 0.46
PRMT1 Q99873 1/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PLIN1 O60240 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981421 1.00 AKR1C1 (0.53) AKR1C1CES2CES1AKR1C3MAPT
SCHEMBL25285472 0.89 CES2 (0.57) AKR1C1CES2CES1MAPTKMT2A
SCHEMBL28221301 0.87 KMT2A (0.50) CES2CES1MAPTKMT2AALDH1A1
SCHEMBL38654764 0.84 PARP1 (0.47) AKR1C1MAPTKMT2AALDH1A1HPGD
SCHEMBL38654565 0.83 KDM4E (0.63) AKR1C1CES2CES1AKR1C3MAPT
SCHEMBL5145449 0.83 MAPT (0.67) MAPTKMT2ALMNAALDH1A1KDM4E
SCHEMBL38654638 0.83 CES2 (0.62) CES2CES1MAPTKMT2ALMNA
SCHEMBL38655937 0.82 CES1 (0.63) CES2CES1MAPTKMT2AALDH1A1
SCHEMBL1804115 0.80 AKR1C3 (0.61) AKR1C1AKR1C3MAPTKMT2ALMNA
SCHEMBL1804114 0.80 AKR1C3 (0.61) AKR1C1AKR1C3MAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113443974-A Method for preparing phenanthrene derivative from biphenyl ketene 武汉理工大学 2021-09-28 CN disclosed
CN-103739465-A Synthesis method of 1, 3-diphenyl-2-bromo-2-propene-1-one ANHUI RUISAI BIOCHEMICAL TECHNOLOGY CO LTD 2014-04-23 CN disclosed
CN-103739465-A Synthesis method of 1, 3-diphenyl-2-bromo-2-propene-1-one ANHUI RUISAI BIOCHEMICAL TECHNOLOGY CO LTD 2014-04-23 CN disclosed
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2005-07-07 US disclosed
US-6906105-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP (US) 2005-06-14 US disclosed
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2003-02-06 US disclosed
US-6462075-B1 USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2002-10-08 US disclosed
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN, J. PHILLIP 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040029-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA AKR1C1 195/4885CES2 3415/4885CES1 811/4885
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA AKR1C1 313/4885CES2 3406/4885CES1 829/4885
US-20030027830-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 AKR1C1 191/4885CES2 3201/4885CES1 1454/4885
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 AKR1C1 191/4885CES2 3201/4885CES1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.